Manufacturers report positive data for ciltacabtagene autoleucel for heavily pretreated relapsed/refractory multiple myeloma

The updated results – from the Phase Ib/II CARTITUDE-1 study – showed an overall response rate of 98% with a longer-term follow-up at a median of 18 months. In addition, 66% of patients were progression free and alive with an overall survival of 81%.

Source:

PharmaTimes